Beijing Science Sun Pharmaceutical Co Ltd

The company maintains a strong liquidity position, with a current ratio of 18.28, indicating that it holds significantly more current assets than current liabilities. However, its free cash flow is negative at -45.09 million CNY, driven by capital expenditures of -100.28 million CNY, suggesting ongoing investment in operations. The debt-to-equity ratio is very low at 0.01, reflecting a conservative capital structure with minimal leverage. Profitability metrics are modest, with a return on equity (ROE) of 0.43% and a return on assets (ROA) of 0.41%, both below the typical thresholds for pharmaceutical firms, which often aim for ROE above 10% and ROA above 5%. The company's operating margin is 3.07% (12.40 million CNY operating income on 404.72 million CNY revenue), which is significantly below the median for the industry. The company's revenue is concentrated in a single geographic market, with all disclosed revenue generated in China. There is no indication of international operations or revenue diversification in the latest financials. The company does not report segment-level revenue, but its product portfolio is centered on generic and branded pharmaceuticals, with no disclosed R&D or biotechnology segments. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. The free cash flow is expected to remain negative due to continued capital expenditures, but the company's strong equity base and low debt position provide a buffer against liquidity risk. The risk assessment highlights a medium liquidity risk due to the negative net cash position after subtracting total debt. While the company has a low dilution risk, the negative free cash flow and capital expenditures suggest potential pressure to raise additional capital in the near term. No dilution events were disclosed in the latest filings, and the shares outstanding remain unchanged between basic and diluted shares. Recent filings and transcripts do not indicate any material events or strategic shifts. The company continues to operate within its core pharmaceutical business, with no disclosed M&A activity or major product launches in the latest reporting period.